Differences in patients underlying health may account for part of the signal
Since 2015, the humanized anti-CD22 monoclonal antibody epratuzumab has been investigated for the treatment of SLE, holding promise for patients with moderate to severe active disease (142144)
An increased risk of GI side effects, including nausea, vomiting, and diarrhoea, is consistently reported: these events are attributed to the GLP-1RA component of the therapy, while an elevated risk of genital infections is associated with the SGLT2i component
Intestinal signals are relayed through the gut-brain axis via vagal and hypothalamic pathways, coordinating appetite, energy expenditure, and fat storage
Genetic epidemiology of the carnitine transporter OCTN2 gene in a Japanese population and phenotypic characterization in Japanese pedigrees with primary systemic carnitine deficiency
-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo
.png)
